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Objectives: To synthesize dihydro-pyrimidine-5-carbonitrile derivatives (5e23), as an extension of the previous series, and to evaluate their anticonvulsant potential.
Methods:
The designed compounds were synthesized and characterized using infrared (IR), nuclear magnetic resonance (NMR) and mass spectroscopy and were evaluated for anticonvulsant activity using the maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole (scPTZ) methods. Compounds with appreciable activity were investigated for their neurotoxicity using the rotarod test.
Introduction
Hybrid molecules, an emerging trend containing two or more structural domains, acting on the same or different targets have been reported to exhibit diverse pharmacological activities, including anticonvulsant activity. Recently, following the hybrid approach, compounds containing a combination of pyridines and pyrrolidones 1 (I) and thiazoles coupled to an oxoquinazoline moiety (II) have been synthesized, some of which exhibit comparable or even higher anticonvulsant activity 2 than the standard drug phenytoin (Figure 1) .
Among various heterocycles, pyrimidine derivatives are quite significant because they have been found to possess diverse pharmacological activities. 3e5 The well-known anticonvulsant drugs phenobarbitone (III) and primidone (IV) possess a dihydropyrimidine ring (Figure 2) .
Similarly, Schiff bases have been reported to elicit such activities. 6, 7 Due to the anticonvulsant activities of pyrimidine and Schiff bases, synergistic activity was expected upon attaching the two moieties. In this context, we previously synthesized 6-oxo-4-(4-methoxy-phenyl)-1,6-dihydropyrimidine-5-carbonitrile derivatives as anticonvulsants. Among these derivatives, compounds with bromo (V) and nitro substitution (VI) on ring C were found to be the most active ( Figure 3 ) with lower neurotoxicity. 8 Following this, 8 we have now synthesized newer derivatives (5e23) by replacing the methoxy group with hydrogen and chloro groups on ring A (Figure 4 ) to examine the effect of increasing the lipophilicity on anticonvulsant activity using the MES 9,10 and scPTZ 11 methods. Compounds with appreciable activity were investigated for neurotoxicity using the rotarod 12 test.
Materials and Methods

Chemistry
The reagents/chemicals/solvents used during the course of these studies were procured from Merck (India), SD Fine and CDH Laboratories as 'synthesis grade' and were used without purification. Melting points (mp) were recorded in open glass capillaries using a Kjeldahl flask containing liquid paraffin. The purity of the compounds was investigated by thin layer chromatography (TLC) on silica gel G plates using benzene:acetone (7:3) as the solvent system. Spots were located either under ultraviolet (UV) light or through exposure to iodine vapours.
IR spectra were recorded using a Bruker alpha-T spectrophotometer. 1 H-NMR spectra were recorded on a Bruker Avance 400 MHz instrument in CDCl 3 or DMSO-d 6 using tetramethylsilane [(CH 3 ) 4 Si] (TMS) as an internal standard. The 13 C-NMR spectra of the compounds were recorded on a Bruker Avance 100 MHz instrument in DMSO-d 6 . Chemical shifts (d) are reported in parts per million (ppm) downfield from TMS, and coupling constants (J) are reported in hertz. Mass spectra were recorded using a Waters SYNAPT UPLC-MS/MS operating with Mass Linux V4.1 software. Elemental analysis (C, H, N) was performed using a PerkinElmer model 240 analyser, and elements were found within AE 0.4% of the theoretical values.
General procedure for the synthesis of 2-mercapto-6-oxo-4-aryl-1,6-dihydropyrimidine-5-carbonitrile derivatives (1e2) These derivatives were synthesized following the previously reported method. 13 2-Mercapto-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitrile General procedure for the synthesis of 2-hydrazinyl-6-oxo-4-aryl -1,6-dihydropyrimidine-5-carbonitrile (3e4)
These compounds were synthesized following the previously reported method. 13 2-Hydrazinyl-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitrile
General procedure for the synthesis of 6-oxo-4-aryl-1,6-dihydropyrimidine-5-carbonitrile derivatives (5e23)
Compound 3 or 4 (1 mmol) was dissolved in a mixture of acetic acid and absolute ethanol (2:8). Substituted acetophenone was added to this solution and refluxed for 2e3 h. The solvent was concentrated and kept in a refrigerator overnight. The precipitate was separated, filtered and recrystallized from methanol (Scheme 1). 
Pharmacology
The female Swiss albino mice used in this study were housed and used following a previously described method. 8 
Anticonvulsant activity
The synthesized compounds were evaluated for anticonvulsant activity using the MES 9,10 and scPTZ 11 methods with phenytoin and carbamazepine as standards. The MES test was performed using an electro-convulsometer (Ugo Basile 57800, Comerio VA, Italy).
Maximal electroshock (MES) test. This test was performed following a previously reported method.
9,10
Subcutaneous pentylenetetrazole (scPTZ) seizure threshold test. scPTZ 11 was performed using the reported method by administering PTZ at a dose 11 of 60 mgkg À1 . 
Scheme 1:
Neurotoxicity Neurotoxicity was examined 12 using a previously reported method.
Log P determination
The values of Log P were calculated using the software 'ChemDraw Ultra 8.0'.
Results and discussion
The synthesis of 6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitrile derivatives (5e23) was conducted by refluxing compound 3 or 4 with different substituted acetophenones for 2e3 h in a mixture of acetic acid and absolute ethanol (2:8). The formation of Schiff bases involved the attack of nitrogen as a nucleophile on the carbonyl group, followed by deprotonation of nitrogen, and finally displacement of a water molecule, leaving a C]N bond.
The required intermediate, compound 3 or 4, was obtained upon nucleophilic attack by hydrazine hydrate. Compound 1 or 2 was synthesized using a modified Biginelli condensation 14 with aromatic aldehyde, ethyl cyanoacetate and thiourea in the presence of potassium carbonate.
The identities of all compounds were elucidated by IR, NMR and mass spectrometry. The peak for C]O was observed in the region of 1655e1703 cm À1 . The peak for C^N peak appeared in the region of 2208e2224 cm À1 . A sharp peak in the range of 3137e3283 cm À1 indicated the presence of a NH group. The formation of Schiff base was confirmed by the absence of a NH 2 peak and the presence of a peak for C]N in the range of 1622e1632 cm À1 .
In the 1 H-NMR data, characteristic peaks with appropriate multiplicities were observed at different chemical shift values. In the case of fluoro-substituted compounds (11 & 21) , coupling was observed between fluorine and hydrogens (same spin of 1 / 2 ), which resulted in a triplet at d values of 7.02 and 7.19 ppm. In the mass spectra, M þ þ2 peaks were observed for compounds possessing chlorine and bromine atoms. These compounds were assessed for their anticonvulsant potential using the MES and scPTZ methods. Following administration of the compounds at doses of 30,100 and 300 mgkg À1 , anticonvulsant activity was recorded time intervals of 0.5 and 4 h using phenytoin and carbamazepine as the reference drugs. Neurotoxicity screening of a few selected compounds was performed using the rotarod test method. From the anticonvulsant evaluation, compounds 7, 9, 10, 13, 14, 16, 18, 19 and 22 were found to be moderately active. Nitro (17) and bromo substitution (23) on ring C and chloro substitution on ring A (Figure 4 ) were found to be the most active. Both of these compounds exhibited activity in both the MES and scPTZ models at the lower dose of 30 mgkg À1 at 0.5 and 4 h. The activity of these compounds was found to be comparable to that of the reference drug phenytoin and higher than that of carbamazepine. Compounds 6, 8, 11, 12, 15, 20 and 21 were the least active, and compound 5 was found to be inactive in both models (Table 1) . During the neurotoxicity screening, it was observed that compounds 17 and 23 did not present any signs of motor impairment, even at higher doses.
The Log P values for nitro-and bromo-substituted compounds ( Figure 3 ) were found to be higher in the present series compared to those in the previous one 8 (Table 2 ). In addition, compounds 17 and 23 of this series exhibited anticonvulsant activity at a lower dose of 30 mgkg À1 after 0.5 and 4 h. From the results, it is evident that increased values of Log P, i.e., increased lipophilicity, led to increased anticonvulsant activity. In addition, the most active compounds of this series did not exhibit any signs of neurotoxicity even at higher doses, which were observed in the previous series. Due to this property of increased a cLog P values were determined using the octanol-phosphate buffer method; experimental values were calculated using ChemDraw Ultra 8.0. lipophilicity, these compounds are expected to have a quick onset of action.
Based on the above results, the following conclusions can be drawn:
i. Increased lipophilicity in ring A increases anticonvulsant activity. ii. In both the previous and current series, the NO 2 -substituted compound was found to be the most active. This result indicates that increased lipophilicity on ring C does not have a significant effect on anticonvulsant activity. iii. The most active compounds of the series did not present any signs of neurotoxicity.
Conclusion
Nineteen new 6-oxo-4-aryl-1,6-dihydropyrimidine-5-carbonitrile derivatives were synthesized. Among these newer derivatives, compounds 17 and 23 emerged as the lead anticonvulsant agents. The anticonvulsant activity of the compounds in this series was found to be better than that in the previous series. Compounds 17 and 23 exhibited activity at a lower dose of 30 mgkg À1 at 0.5 and 4 h. In contrast, the most active compounds of the previous series exhibited activity at doses of 30 mgkg À1 at 0.5 h and 100 mgkg À1 at 4 h.
The anticonvulsant activity of compounds 17 and 23 was comparable to that of phenytoin and higher than that of carbamazepine. In addition to better anticonvulsant activity, compounds 17 and 23 did not show any motor impairment, which was observed in the previous series. The better results for this series of compounds in terms of anticonvulsant activity and neurotoxicity are a consequence of the increased lipophilicity.
